Research subject
Development of Anti-ebola virus drug
Kyushu University Hospital
Principal investigator
Jiro Yauda
Contact (email)
Study outline
The mortality of ebola virus disease is very bad. According to the recent reports, several effective antibody for ebora virus has been succeefuly developed. However, it is not so easy to realize the low temperature strage in Africa. Under this situation, new orally available medicine is highly expected. We have discovered several compounds of highly active anti-ebora virus growth. Recently, we successfully obrained several better active compounds (IC50=<100nM). At present, we prepare the animal model experiment in USA (Boston University) by using our active compounds. Based on the activity data from the animal model experimentsl, we would like to fix the goal of our compound for clinical trials.
  • Area of the study
    Other than cancer
    Development items
    Regulatory approval
    Main country where studies are conducted
    Led by a country abroad
    Leading country name:(United States)
    Number of participating countries, Number of participating institutions
    Number of participating countries:---, Number of participating institutions:---
    Participating countries' names
    Study design
    Development phase
    Sample size
  • Website
    Not registered
    Intellectual property
    Preclinical study
    Not completed yet
    Sponsoring company
    Planning of licensing-out
    Not planned
    Domestic funding
    Funding abroad
    Not completed yet in any countries
    Procurement of investigational product
    Not completed yet in any countries
  • Steering Committee
    Development roadmap
    Not fixed yet
    Stage of the study
    IRB application
    Data management
    Consultation with regulatory authorities
Current issues & challenges
(request for support, etc.)


If you wish to collaborate on a listed project, or if you wish to propose a joint research project, please fill in the Contact Form and submit it.